12 Healthcare Stocks with Insider Buying in 2025

Page 4 of 10

7. Phibro Animal Health Corporation (NASDAQ:PAHC)

Insider Shares: 50.06%

Phibro Animal Health Corporation (NASDAQ:PAHC) reported strong growth in 2025, driven by expanded product lines and rising global demand. Operating across about 90 countries, the company serves both food and companion animals through its portfolio of medicated feed additives (MFAs), nutritional products, vaccines, and specialty ingredients.

For fiscal Q4 2025, Phibro Animal Health Corporation (NASDAQ:PAHC)’s net sales surged 39% to $378.7 million, fueled by a 53% increase in its Animal Health segment. MFA sales jumped 77%, largely from the successful acquisition and integration of Zoetis’ MFA portfolio and robust demand in Latin America. Specialty nutritional products and vaccines also contributed to gains. Overall, fiscal 2025 net sales rose 27% to $1.29 billion, with significant improvements in net income and adjusted EBITDA.

The Zoetis acquisition, which added more than 37 products and six manufacturing sites worldwide, has been central to Phibro’s recent momentum. The firm is also expanding in the companion animal market and seeing global adoption of OmniGen-AF, a nutritional supplement for the dairy industry.

Investor confidence has followed these results. PAHC’s stock is up more than 80% year-to-date in 2025, outpacing both peers and the broader market. Analysts have raised earnings forecasts for fiscal 2025 and 2026, reflecting optimism around continued growth. Looking ahead, PAHC projects $1.43 to $1.48 billion in revenue and $225–$235 million in adjusted EBITDA for fiscal 2026, underscoring confidence in its trajectory.

Page 4 of 10